Objectives: The current study analyzed the sociodemographic, treatment-related, and other substance use characteristics among pregnant women who reported alcohol use and were admitted to substance use treatment for the first time.
Methods: The Treatment Episode Data Set-Admission (TEDS-A) between 1992 and 2012 was used for conducting a cross-sectional study.
Results: Among pregnant women admitted to substance use treatment for the first time (N=166,863), 43.1% reported alcohol use of whom half used alcohol as the primary drug of choice. The proportion of pregnant women reporting any alcohol use declined over the study period, while the proportions of subgroups within pregnant women reporting alcohol use remained stable within the population. Those reporting alcohol use only notably had the highest proportion of women aged 40 or older and non-Hispanic White who were more educated, employed, and married, compared to those reporting alcohol use as primary but also other substance use and those reporting other substance as primary drug of choice. Those reporting only alcohol also were more likely to be referred by the justice system to outpatient treatment. Marijuana was the most popular co-used substance among pregnant women who use alcohol as primary drug of choice in the dataset.
Conclusions: Differences in sociodemographic, treatment-related, and other substance use characteristics between the three subgroups may help inform public health interventions aimed at mitigating the effects of prenatal alcohol use on maternal and child health.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jsat.2017.09.010 | DOI Listing |
PLoS One
January 2025
Faculty of Psychology, Universitas Ahmad Dahlan, Yogyakarta, Indonesia.
Indonesia is still the second-highest tuberculosis burden country in the world. The antituberculosis adverse drug reaction and adherence may influence the success of treatment. The objective of this study is to define the model for predicting the adherence in tuberculosis patients, based on the increased level of liver enzymes.
View Article and Find Full Text PDFPLoS One
January 2025
Henan Key Laboratory of Fertility Protection and Aristogenesis, Luohe Central Hospital, Luohe, Henan Province, People's Republic of China.
Purpose: To evaluate the clinical performance of expanded non-invasive prenatal testing (NIPT-plus) and compare its effectiveness in screening for chromosomal aneuploidies with that of NIPT.
Methods: Screening results, confirmatory invasive testing results, and follow-up data from pregnant women who underwent either NIPT (6792 cases) or NIPT-Plus (5237 cases) testing at Luohe Central Hospital, China, from January 2019 to June 2023 were collected. The positive predictive value (PPV), sensitivity, specificity, and other indicators for different types of chromosomal abnormalities in NIPT/NIPT-plus screening were calculated.
Am J Reprod Immunol
February 2025
Department of Anthropology, University of California, Los Angeles, California, USA.
Problem: Regulatory B-cells (Bregs, CD19CD24CD38) are a specialized B-cell subset that suppresses immune responses and potentially contribute to the maintenance of an immune-privileged environment for fetal development during pregnancy. However, little is known about the surrounding immunological environment of Bregs in gestational physiology. The relationship of regulatory T-cells (Tregs, CD4CD25CD127FoxP3) to Bregs in coordinating immunoregulation during pregnancy is unknown.
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.
Aims: Physiological changes during pregnancy can infuence the performance of blood glucose meters. This study aimed to evaluate the analytical and clinical accuracy of glucose meters in pregnant women with hyperglycaemia.
Materials And Methods: Glucose was measured by four commonly used meters among consecutive women with diabetes in pregnancy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!